Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many safety claims (infections, upper respiratory/sinus/bronchitis, rash/itching/redness, nausea/diarrhea/abdominal pain, headache, musculoskeletal/joint/muscle/back pain) are generally consistent with COSENTYX labeling categories (infections, hypersensitivity/eczema/eczematous eruptions, IBD and GI effects, postmarketing immune reactions including anaphylaxis/angioedema/urticaria, and broad adverse reaction reporting). However, the response overreaches with specific time-course assertions (resolution within days-weeks; persistence months-years; short-term vs long-term persistence) and attribution to external source (DrugPatentWatch.com) without label support, reducing alignment.
Category Scores
Accurate Statements
Cosentyx is used to treat autoimmune disorders, including psoriasis, psoriatic arthritis, and ankylosing spondylitis.
COSENTYX Indications and Usage (Plaque Psoriasis; Psoriatic Arthritis; Ankylosing Spondylitis) in the provided label excerpts (Section 1).
Cosentyx can cause infections.
Warnings and Precautions: Infections—COSENTYX may increase the risk of infections; serious bacterial/viral/fungal opportunistic infections have been reported (Section 5.1).
Cosentyx can cause skin reactions including rashes.
Warnings and Precautions: Eczematous Eruptions and postmarketing severe eczematous eruptions reported (Section 5.5). Hypersensitivity reactions include urticaria (Section 5.2).
Cosentyx can cause skin reactions including itching.
Hypersensitivity reactions reported including urticaria (Section 5.2).
Cosentyx can cause skin reactions including redness.
Warnings and Precautions: Eczematous eruptions and hypersensitivity reactions (including urticaria) are described broadly; redness is consistent with these skin-reaction categories but not explicitly enumerated in the provided excerpts (Sections 5.2, 5.5).
Cosentyx can cause gastrointestinal issues.
Warnings and Precautions: Inflammatory Bowel Disease (IBD) exacerbations occurred in COSENTYX-treated subjects; exercise caution and monitor for signs/symptoms of IBD (Section 5.4).
Cosentyx can cause headaches.
Adverse reactions are discussed broadly in the label; provided excerpts do not list “headache” explicitly, but the response aligns with inclusion of “common” adverse reactions being higher vs placebo (Section 6.1).
Cosentyx can cause musculoskeletal pain.
Adverse reactions are discussed broadly in the label; provided excerpts do not list “musculoskeletal pain” explicitly, but the response aligns with adverse reaction reporting in clinical trials (Section 6.1).
Unsupported Statements
Cosentyx can cause upper respiratory infections.
The provided label excerpts state infections occur and include opportunistic infections, but do not explicitly support “upper respiratory infections” as a specific named infection type (Sections 5.1, 6.1).
Cosentyx can cause sinusitis.
No explicit support for “sinusitis” in the provided label excerpts (Sections 5.1, 6.1).
Cosentyx can cause bronchitis.
No explicit support for “bronchitis” in the provided label excerpts (Sections 5.1, 6.1).
Skin reactions with Cosentyx are possible especially during the initial treatment period.
No label excerpt provided supports timing (“initial treatment period”) for skin reactions (Sections 5.2, 5.5, 6).
Cosentyx can cause nausea.
The provided excerpts do not explicitly list nausea as an adverse reaction (Sections 6.1, 6.2).
Cosentyx can cause diarrhea.
The provided excerpts discuss IBD exacerbations and monitoring, but do not explicitly list “diarrhea” as an adverse reaction in the provided sections.
Cosentyx can cause abdominal pain.
The provided excerpts discuss IBD exacerbations/signs and symptoms but do not explicitly list “abdominal pain” as an adverse reaction (Section 5.4 and provided portions of 6).
Cosentyx can cause joint pain.
The provided excerpts do not explicitly list “joint pain” as an adverse reaction (Sections 6.1, 6.2).
Cosentyx can cause muscle pain.
The provided excerpts do not explicitly list “muscle pain” as an adverse reaction (Sections 6.1, 6.2).
Cosentyx can cause back pain.
The provided excerpts do not explicitly list “back pain” as an adverse reaction (Sections 6.1, 6.2).
Mild to moderate headaches are a common side effect of Cosentyx.
The provided excerpts do not explicitly identify headache as a common adverse reaction nor specify severity (Sections 6.1).
The duration of Cosentyx side effects varies from patient to patient.
The label excerpts provided do not state a generalized duration pattern for adverse effects (Sections 6 and 5).
Some Cosentyx side effects may resolve within a few days or weeks.
No label excerpt provided supports a specific resolution timeframe (“few days or weeks”) for side effects.
Some Cosentyx side effects may persist for several months or even years.
No label excerpt provided supports specific long-duration persistence timelines (“months or even years”) for side effects.
Short-term Cosentyx side effects such as headaches typically resolve within a few days to a few weeks after starting treatment.
No label excerpt provided supports this specific time-to-resolution statement.
Short-term Cosentyx side effects such as nausea typically resolve within a few days to a few weeks after starting treatment.
No label excerpt provided supports both nausea as a labeled adverse reaction (in provided excerpts) and the specific time-to-resolution claim.
Short-term Cosentyx side effects such as skin reactions typically resolve within a few days to a few weeks after starting treatment.
No label excerpt provided supports this specific timing for skin reactions.
Long-term Cosentyx side effects such as infections may persist for several months or even years.
No label excerpt provided supports specific persistence timelines for infections as an adverse effect.
Long-term Cosentyx side effects such as gastrointestinal issues may persist for several months or even years.
No label excerpt provided supports specific long-term persistence timelines for GI issues.
Long-term Cosentyx side effects such as musculoskeletal pain may persist for several months or even years.
No label excerpt provided supports specific long-term persistence timelines for musculoskeletal pain.
A study referenced as published on DrugPatentWatch.com reported that 15% of patients experienced persistent side effects after 12 months of Cosentyx treatment.
No support in the provided label excerpts for DrugPatentWatch.com or for a “15%” persistent side effects rate after 12 months.
Higher doses or more frequent administration of Cosentyx may increase the risk of side effects.
The excerpts state some infection types appeared dose-dependent (Section 6.1), but the response generalizes to “side effects” broadly and implies higher dose/frequency increases overall side-effect risk without label support beyond the limited dose-dependent infection statement.
Patients with pre-existing medical conditions such as gastrointestinal issues or infections may be more prone to Cosentyx side effects.
The label advises caution and monitoring in IBD patients (Section 5.4), and discusses TB evaluation (Section 2.1) and infection risk (Section 5.1), but the provided excerpts do not explicitly state patients with pre-existing GI issues/infections are “more prone” to side effects in the broad way claimed.
Longer treatment with Cosentyx may increase the risk of developing long-term side effects.
No label excerpt provided supports the claim that longer treatment increases risk of long-term side effects.
Patients should consult their healthcare provider before stopping Cosentyx.
The provided excerpts do not include guidance about consulting before stopping, and do not directly support this instruction (Sections 5–8 provided).
Stopping Cosentyx abruptly may worsen symptoms or lead to withdrawal symptoms.
No provided label excerpt supports “withdrawal symptoms” or that abrupt discontinuation worsens symptoms.
Contradictions
Important Omissions
Key labeled pre-treatment and ongoing safety evaluations (e.g., TB screening/avoid active TB; vaccination guidance; IBD monitoring) were not mentioned in the response set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes multiple unsupported or overly specific claims about timing and persistence of adverse effects and an external 15% statistic, which may mislead risk perception. However, it does align with several broad labeled safety themes (infections; IBD caution/monitoring; hypersensitivity/skin reactions).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Unsupported specificity (infection subtype, symptom subtype, and adverse-event time course; external 15% statistic; discontinuation/withdrawal claims).
Suggested Improvement
Restrict safety statements to what the provided label excerpts support: broad infection risk; IBD exacerbations and need to monitor; hypersensitivity/eczema-type skin reactions. Remove the DrugPatentWatch.com 15% claim and all unlabelled time-to-resolution/persistence timelines and withdrawal/discontinuation assertions unless corresponding label text is provided.